leisure time -WSS

leisure time

author：fashion 2025-10-01 23:39:21 - browse：47684

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Stanford president to resign after investigation of research

entertainment

WSS

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Stanford updates investigation of president’s past research

Cigna, Humana reportedly in talks to merge

30 years of 'Listening to Prozac'

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

leisure time

leisure time

Gilead needs Arcellx more than ever

focus

Jerome Adams on the need for new antivirals for Covid

ReNAgade cuts staff seven months after raising $300 million

How to save PrEP access — and even expand it

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Virginia high school admissions case could be legal follow

Rep. Raul Ruiz on the physician shortage and more

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Will the market for weight loss drugs really reach $100 billion?

Alkermes shareholders re

ReNAgade cuts staff seven months after raising $300 million

explore

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

As biotech industry slumps, bioscience job market is upside down

'Reaching a detente': STAT's Helen Branswell on covering Covid

FDA investigates CAR

Stanford updates investigation of president’s past research

entertainment

entertainment

focus

hotspot